Log in to your Inderes Free account to see all free content on this page.
Create account

I-tech

63.00 SEK

-2.78 %

Less than 1K followers

ITECH

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-2.78 %
+15.17 %
+42.53 %
+20.69 %
-1.25 %
-35.71 %
+72.13 %
-14.40 %
+155.42 %

I-tech operates in marine technology. The company conducts research and development of substances that inhibit marine fouling on ship hulls. In addition, the products can be used for various marine installations in fish farming and offshore. Customers are found in the marine paint industry and among other players in the shipping industry. I-Tech was founded in 2000 and has its headquarters in Mölndal.

Read more
Market cap
755.86M SEK
Turnover
1M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21.8.
2026

Interim report Q2'26

16.10.
2026

Interim report Q3'26

ShowingAll content types
Third party research

I-tech: 2026 looking better than feared - ABG

* Q1: Organic growth of +7% despite tough comps (vs. ABGSCe -15%) * Customer with financial constraints back to normal order cadence * We raise organic growth ests. for '26e to +25% (+15% previously) Q1 results Q1 sales were much stronger than we expected...

I-tech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

I-tech: Significant beat across the PL - ABG

* Sales +27% vs. ABGSCe, EBIT SEK 19m vs. ABGSCe 9.8m * A beat on all line items, despite very tough comps * Gross margin 60% (56% LY), though may soften on raw material prices Much stronger growth than expected Sales came in above expectations at SEK...

I-tech
Third party research

I-tech: Announce extension of Selektope until Dec '26 - ABG

* Approval for Selektope extended again, now until Dec '26 * Ongoing process could not be finalised within timeframe * I-Tech views this as positive; invests in new EOGRT study Approval extended again, until Dec '26 The European Commission and the Standing...

I-tech
Third party research

I-tech: Another growth breather in Q1e - ABG

* Q1e sales 42m (57m), adj. EBIT SEK 9.8m (18m) * Updated FX forecasts, we raise '26e-'28e sales by 4-5% * Trading at '26e-'28e EV/EBIT of 8x-3x Q1 expectations We estimate sales of SEK 42m (57m), -27% y-o-y (-15%% org., -12% FX). I-Tech is facing tough...

I-tech
Third party research

I-tech: A pause in pace, not the story - ABG

* Q4: -23% organic growth (vs. ABGSCe -12%) * Financially constrained customer weighed on ’25 org. growth * Long-term potential intact, expect continued CMP growth in '26e 2025, a mixed financial year Q4 organic growth came in below our estimate at -...

I-tech
Third party research

I-tech: Customer pullback weighing on growth - ABG

Sales -13% vs. ABGSCe, EBIT SEK 7.6m vs. ABGSCe 9.4m * Three coating products launched in Korea in Q4 * Sizeable customer with financial constraints impacting volumes Q4 results I-Tech reported sales of SEK 39m, falling 13% short of our estimate (-33...

I-tech
Third party research

I-tech: No easy lap into Q4e - ABG

* Q4e sales SEK 45m (58m), adj. EBIT SEK 10m (19m) * We cut '26e-'27e sales and EBIT by 10% and 22-19%, respectively * Lowered growth assumptions for CMP Tough comps in Q4e We estimate Q4 sales of SEK 45m, -23% y-o-y (-12% organic, -11% FX). I-Tech is...

I-tech
Third party research

I-tech: Proposed non-renewal of Selektope in the EU - ABG

* European Commission drafts proposal for non-renewal of Selektope* Limited impact on near-term estimates, EU ~2% of total sales* Voting expected to occur some time in H1'26, final decision in mid-26European Commission drafts proposal for non-renewal...

I-tech

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.